The Imfinzi Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s delve into the journey of Imfinzi (durvalumab) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Imfinzi (durvalumab) Mechanism of Action: PD-L1 inhibitor, which helps the immune […]
The Addyi Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s delve into the journey of Addyi (flibanserin) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Addyi (flibanserin) Mechanism of Action: Serotonin 1A receptor agonist and […]
Navigating the FDA Complete Response Letter: The Xeljanz Resubmission Journey
Hello Regulatory Scientists, Today, let’s dive into the fascinating journey of Xeljanz (tofacitinib) from receiving an FDA Complete Response Letter (CRL) to eventual approval. This case study not only sheds light on the intricacies of regulatory processes but also offers valuable lessons for those developing drugs today. Regulatory History and Initial Submission Drug: Xeljanz (tofacitinib) […]
The Opdivo Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s explore the journey of Opdivo (nivolumab) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Opdivo (nivolumab) Mechanism of Action: PD-1 inhibitor, which helps the immune […]
The Jardiance Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s explore the journey of Jardiance (empagliflozin) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Jardiance (empagliflozin) Mechanism of Action: Sodium-glucose co-transporter 2 (SGLT2) inhibitor, which […]
The Zydelig Resubmission Journey: Navigating the Path to FDA Approval
Hello Regulatory Scientists, Today, let’s explore the journey of Zydelig (idelalisib) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case studyprovides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Zydelig (idelalisib)Mechanism of Action: PI3K delta inhibitor, which helps to inhibit the […]
The Kalydeco Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s dive into the journey of Kalydeco (ivacaftor) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Kalydeco (ivacaftor) Mechanism of Action: CFTR potentiator, which helps to […]
The Brilinta Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s delve into the journey of Brilinta (ticagrelor) from receiving an FDA Complete Response Letter (CRL) to achieving approval. Understanding this case provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Brilinta (ticagrelor) Mechanism of Action: P2Y12 receptor antagonist, which inhibits […]
The Farxiga Resubmission Journey: Turning an FDA CRL into Success
Hello Regulatory Scientists, Today, let’s explore the journey of Farxiga (dapagliflozin) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case provides invaluable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Farxiga (dapagliflozin) Mechanism of Action: Sodium-glucose co-transporter 2 (SGLT2) inhibitor Indication: Type […]
Turning Setbacks into Success: The Eylea Resubmission Journey
Hello Regulatory Scientists, Let’s delve into the journey of Eylea (aflibercept) from receiving an FDA Complete Response Letter (CRL) to its eventual approval. Understanding this case provides valuable insights and lessons for those developing new drugs today. Regulatory History and Initial Submission Drug: Eylea (aflibercept) Mechanism of Action: Vascular Endothelial Growth Factor (VEGF) inhibitor Indication: […]